Clinical Trials Logo

Hypertriglyceridemia clinical trials

View clinical trials related to Hypertriglyceridemia.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT03342807 Not yet recruiting - Clinical trials for Hypertriglyceridemia

Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis

Start date: November 2017
Phase: Phase 4
Study type: Interventional

To investigate an economical and effective way to reduce the level of serum triglyceride in patients with hypertriglyceridemia-induced acute pancreatitis.

NCT ID: NCT02625870 Not yet recruiting - Clinical trials for Hypertriglyceridemia

Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides

OMEELVHT
Start date: December 2015
Phase: Phase 3
Study type: Interventional

The trial was a double-blind, randomized, parallel-group study comparing Omega-3-Acid Ethyl Esters 90 Soft Capsules and placebo. The primary objective of the present study was to evaluate the efficacy and safety of Omega-3-Acid Ethyl Esters 90 Soft Capsules in subjects with severe hypertriglyceridemia (TGs ≥500 mg/dL but <2000 mg/dL).

NCT ID: NCT01577056 Not yet recruiting - Clinical trials for Familial Hypercholesterolaemia

Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils

FIFH
Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether fish oil supplementation is effective in the treatment of abnormal fat metabolism in subjects with elevated cholesterolaemia.

NCT ID: NCT01086163 Not yet recruiting - Clinical trials for Coronary Artery Disease

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

OMPA-CAD
Start date: October 2010
Phase: N/A
Study type: Observational

Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently approved by the Federal authorities for the drug management of post-infarction patients with high blood triglycerides. Given the growing length of CAD progression, it is pertinent that many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet properties of PO-3A will be a highly desirable and attractive commodity of this medication. The investigators believe that Omacor®/Lovaza® is ideally positioned for the chronic management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with statins or aspirin. The investigators hypothesize that addition of Omacor may add mild antiplatelet protection for CAD patients. The study objectives are: - To assess the ex vivo effects of Omacor® on platelet function in patients with coronary artery disease (CAD). - To compare ex vivo platelet-related effects after 7 and 14 days of therapy with Omacor and statin combination versus statin alone in patients with chronic stable coronary heart disease. - To establish the relation of changes in platelet activity (if any) with the lipid profile to prove an additional benefit of Omacor® on top of statin and aspirin.